A few years ago, we had a listing of the five most significant advances in the treatment of cancer over the decades. These included imatinib, the first oral-targeted drug for chronic myelogenous leukemia (CML) in 2001, and ondansetron, a revolutionary medicine to block nausea caused by chemotherapy in 1990. Even so, history is being made every year at the annual American Society of Clinical Onc...
To access content, please login or purchase a subscription.
